The CNSide catastrophe – Why patient collapse kills a $6 billion dream

When Plus Therapeutics announced its UnitedHealthcare coverage agreement in September 2025, the stock market briefly celebrated. One of America’s largest health insurers, covering 51 million people, had agreed to reimburse CNSide. Except UnitedHealthcare is imploding. In late October 2025, just weeks after the coverage took effect, the company disclosed it expects to lose two-thirds of its Obamacare customers due to rate increases exceeding 25%. The coverage that was supposed to save Plus might simultaneously be destroying the patient population it was designed to reach.

In late October 2025, UnitedHealthcare disclosed that it anticipates losing approximately two-thirds of its Obamacare customer base due to planned rate increases exceeding 25%, driven by higher-than-expected medical costs and underestimated patient morbidity. The company currently maintains 1.7 million Obamacare enrollees. Losing two-thirds means the insurance pool Plus was counting on could shrink to roughly 570,000 people by 2026.

​But there’s a hidden variable in this adoption story. The primary payer backing CNSide, the one that was supposed to unlock adoption, is simultaneously experiencing catastrophic enrollment collapse due to the ACA marketplace crisis. Coverage and patient population are moving in opposite directions.

The CNSide that was and why Plus bought it

To understand where this went wrong, you need to understand what CNSide actually is and why it mattered before Plus inherited it.

CNSide is a cerebrospinal fluid assay that identifies tumor cells in the fluid surrounding the brain and spinal cord. It’s designed to catch a specific horror: leptomeningeal metastases, which happen when cancer spreads to the membrane coating the central nervous system. About 30% of cancer patients eventually develop CNS metastases, making it one of the most common complications of advanced cancer. And until CNSide existed, diagnosis was essentially medieval. The standard approach missed half the cases.​

CNSide changed that. It could identify tumor cells that cytology missed, achieving 56% higher diagnostic yield than standard methods. More importantly, it influenced treatment decisions in 90% of cases where it was used. For cancer patients who would otherwise face palliative care or hospice, this diagnostic test could be the difference between treatment and death.​

By 2020, when the original developers had commercialized CNSide, the platform had accumulated over 11,000 tests across 120+ institutions. Physicians at those institutions knew it. They trusted it. They were using it regularly. This wasn’t theoretical clinical utility. This was proven adoption at scale across the U.S. cancer center network.​

Then, over $300 million in development costs later, Plus Therapeutics acquired the technology. The company’s CEO Marc Hedrick described the moment with genuine enthusiasm. CNSide, he said, represented an “expedited path to revenue and corporate profitability” while the company continued its core radiotherapy pipeline. This made sense on paper. The platform was already proven. Market access was partially established. All Plus needed to do was reignite adoption.​

They announced plans to launch in Texas in summer 2025, followed by rapid national expansion. They achieved CLIA accreditation in September 2025, a federal requirement that unlocks Medicare and Medicaid reimbursement. They signed the UnitedHealthcare agreement covering 51 million people, effective September 15, 2025.​

Everything appeared to be on track. And then the adoption numbers started revealing a problem.

The adoption collapse

Here’s where the data becomes brutal. In August 2025, Plus presented retrospective CNSide data from 613 patients showing 67% had detectable tumor cells. This sounds fine until you do the math. Six hundred and thirteen patients tested since Plus acquired the technology. Spread across what should be a $6 billion annual addressable market. That’s not adoption. That’s barely a pilot program.​

For context: the pre-Plus CNSide platform had performed 11,000 tests since 2020. That’s roughly 2,200 tests per year averaged over five years. Plus’s latest reported cohort of 613 tests represents roughly one quarter of baseline annual testing volume, yet the company is now marketing itself as having just relaunched nationally.

The problem isn’t clinical. The CNSide test works exactly as well as it did before. The problem is patient access, physician awareness, and the sheer inertia of changing diagnostic practices in oncology centers.

When the original developers commercialized CNSide, they had built relationships with 200+ cancer institutions over years. Physicians had incorporated the test into their clinical workflows. Referring oncologists knew to order it. Patients were getting diagnosed who would have been missed.

When Plus took over, it inherited the technology but not the momentum. The institutional relationships largely evaporated. The physician network had to be rebuilt from zero. And here’s the crucial detail: Plus is competing not just against the standard of care (cytology), but against institutional inertia and the reality that many cancer centers that previously used CNSide simply didn’t transfer their ordering patterns to the new operator.

Reddit investors tracking PSTV have noticed this. One comment in October 2025 reads: “CNSide should be printing money by now given the technology and payer coverage, but the numbers suggest nobody is actually ordering it.” Another investor, discussing the UnitedHealthcare agreement in early October, noted: “Coverage is great but it means nothing if physicians don’t know about it or don’t switch their ordering patterns.”

These aren’t professional analysts. They’re retail investors watching the stock price and doing basic math. And the math doesn’t work.

The financial reality: Losses accelerating, adoption stalling

Plus Therapeutics reported Q3 2025 results in late October 2025, and the picture was grim. The company recorded:​

• operating losses of $4.5 million in Q3 2025, up approximately 18% from $3.8 million in Q3 2024. Net losses of $4.4 million in Q3 2025, up 52% from $2.9 million in Q3 2024. Cash position of $16.6 million as of September 30, 2025,​
• at a quarterly burn rate of $4.4 million, Plus has roughly 3.7 quarters of cash runway remaining before insolvency. The company did receive a $1.9 million advance toward a $17.6 million CPRIT grant, which extends the runway, but this is still a company in financial distress with a hemorrhaging balance sheet.​

The devastating part: these losses are increasing despite having just secured national payer coverage and having a proven diagnostic platform ready to deploy. Usually, you’d expect losses to decline as a company scales commercial execution. Instead, they’re accelerating. The company reports “higher compensation and professional fees” drove the increase, which translates to: they’re spending more on sales and management without corresponding revenue acceleration.​

This is the opposite of what was supposed to happen.

Why patient adoption broke

The core issue is deceptively simple, but the implications are devastating. When diagnostic platforms change operators, adoption doesn’t transfer automatically. Physician ordering patterns are sticky. Institutions that were happy with the original CNSide commercialization operator had established workflows, reimbursement arrangements, and relationships. When Plus took over, those relationships had to be rebuilt from scratch.

Meanwhile, standard cytology, the test that CNSide outperforms by 56%, didn’t go anywhere. It’s still available. It’s still reimbursed. It requires no relationship change. For many cancer centers, the barrier to switching to CNSide was never clinical utility (that was proven). It was operational effort and established practice patterns.

Plus faced an additional problem: the company needed to rebuild awareness among oncologists and neurologists who had never used CNSide, while simultaneously re-engaging institutions that had used it under the previous operator. The UnitedHealthcare agreement provided insurance coverage, but insurance coverage means nothing if ordering physicians don’t know about the test, don’t believe it’s better, or don’t want to change their current practices.

One critical detail emerged in the company’s communications: the original CNSide developer had invested over $300 million developing this technology. That’s an enormous sunk cost, but it also reveals something important. The technology was mature. The clinical data was published. The adoption curve had already flattened years ago. Plus wasn’t commercializing an innovative new test. It was trying to resurrect adoption of an existing test that had already cycled through its early adoption phase.​

Early adopters had moved on. Late majority physicians were never going to switch without compelling reasons beyond “our new owner says it’s good.” And the late majority comprises most of clinical practice.

H.C. Wainwright, the analyst firm covering Plus, estimated that CNSide would generate approximately $1 million in revenue in 2025 (essentially the pre-commercialization phase), growing to $38 million by 2032. The analyst reiterated a “Buy” rating but notably lowered the price target from $3 to $2.00 per share in early November, citing dilution from recent equity raises and cautioning that “CNSide has only been launched in Texas as the company works through licensing and regulatory requirements for other states. Therefore, we expect CNSide related revenues to slowly ramp up over the next 12-18 months”.

But here’s the problem that appears nowhere in analyst reports: the national payer you’re counting on is simultaneously experiencing catastrophic enrollment collapse.

The mathematical reality – Coverage doesn’t equal adoption

This is the brutal lesson that biotech companies keep learning and re-learning. Payer coverage is a necessary condition for commercial success, but it’s not sufficient. You also need:

• physician awareness of the product,
• clinical validation that reaches practicing physicians, not just academic journals,
• operational incentives for diagnostic centers to adopt the test,
• demonstrated patient benefit that translates to reimbursement for the oncologist ordering it (not just for Plus running the test).​

CNSide had all of these under the previous operator. But that adoption infrastructure wasn’t portable. When Plus took over, it inherited a shell, a powerful diagnostic technology with clinical proof of concept, but without the commercial relationships and physician networks that had made it work.

The UnitedHealthcare agreement covering 51 million people is real coverage. But if ordering physicians don’t know about it, or if cancer centers prefer their existing diagnostic workflow, that coverage evaporates into theoretical value. It’s like having a store in a building with millions of potential customers but nobody knows you’re open, and changing suppliers requires replacing established vendor relationships.

This isn’t speculation. This is basic math applied to disclosed data.

The hidden crisis

Here’s what the UnitedHealthcare coverage announcement didn’t mention. In October 2025, just weeks after the coverage agreement took effect, UnitedHealthcare disclosed to Wall Street that it expects to lose approximately two-thirds of its Obamacare customer base due to planned premium rate increases exceeding 25%. The company currently serves 1.7 million ACA marketplace enrollees. That number is projected to drop to roughly 570,000 by 2026.​

This matters far more than it initially appears. A significant portion of leptomeningeal metastases patients, the population CNSide is designed to diagnose, are insured through exactly these ACA marketplace plans. When UnitedHealthcare shrinks its Obamacare membership by two-thirds, the addressable market for a test that depends on insurance coverage simultaneously collapses.​

Plus Therapeutics achieved coverage from UnitedHealthcare effective September 15, 2025. The company began commercializing CNSide into a patient population that is simultaneously exiting the insurance pool. The covered population Plus was counting on will be substantially smaller by January 2026, exactly when the company needs revenue acceleration most.

The timeline trap

Here’s where Plus’s financial situation becomes genuinely precarious. The company needs to demonstrate accelerating CNSide adoption to justify the investment they’ve made in the commercialization infrastructure. But adoption acceleration requires time, usually 6-18 months from coverage announcement to material volume changes. Physician behavior changes slowly.

Plus doesn’t have 6-18 months. At current burn rates, the company has less than 12 months of cash runway remaining, even accounting for the CPRIT grant. If patient adoption doesn’t accelerate materially within 3-4 quarters, the company faces a capital raise or a crisis.

This isn’t new for Plus. The company has been dancing on the edge of insolvency for years. In September 2024, PSTV faced Nasdaq delisting over equity shortfall issues. The company regained compliance in August 2025, just weeks before announcing the UnitedHealthcare agreement. The timing wasn’t coincidental. Wall Street expected the UnitedHealthcare announcement to unlock CNSide adoption and drive revenue growth that would solve Plus’s financial problems.​

If that growth doesn’t materialize, we’re looking at another delisting threat, likely leading to a desperation capital raise that would dilute shareholders dramatically.

What happens now

The next 12 months matter. Plus needs to demonstrate that CNSide adoption is accelerating.

If these markers don’t appear in Q4 2025 and Q1 2026 reports, confidence in the thesis collapses. But there’s an additional complication. UnitedHealthcare, the primary payer behind CNSide coverage, expects to lose two-thirds of its Obamacare members by 2026. This means the addressable market for CNSide is shrinking simultaneously with adoption efforts ramping up. Plus Therapeutics doesn’t just need adoption acceleration. It needs adoption acceleration fast enough to offset the patient population exodus from its biggest insurance partner.

For investors watching PSTV, the metrics that matter are more complex than they appear. Track patient volumes. Track revenue. But also track UnitedHealthcare’s ACA membership numbers. When the primary payer backing your coverage is losing millions of patients due to unaffordable premiums, coverage becomes increasingly theoretical. Watch whether Plus can shift adoption toward stable insurance populations (Medicare Advantage, employer plans) fast enough to compensate. That’s the real turnaround question.